Microscopy Research and Technique · مجلد 89 (5) · 687-704
Prostate cancer is a prevalent and serious health concern, ranking among the most frequently diagnosed cancers and a leading cause of cancer-related deaths in men worldwide. Early detection and accurate diagnosis are crucial for improving patient outcomes by limiting disease progression. Histopathological image analysis remains the gold standard for prostate cancer detection; however, manual interpretation is time-consuming and requires specialized expertise. To address these challenges, this study proposes a hybrid deep learning framework that combines an ensemble of transfer-learned CNNs (VGG-16, DenseNet-121, and AlexNet) with a fine-tuned Vision Transformer (ViT). The CNN ensemble extracts rich local features, while the ViT captures global contextual dependencies through a self-attention mechanism and a multilayer perceptron (MLP). Additionally, a cross-attention fusion (CAF) module integrates local and global features, and knowledge distillation (KD) enables a lightweight student network suitable for efficient clinical deployment. The study utilizes the publicly available PANDA dataset for training and testing. Preprocessing steps, including patch generation, gamma correction, and stain deconvolution, enhance image quality and feature representation. A comprehensive evaluation was conducted using standard performance metrics such as accuracy, true positive rate (TPR), true negative rate (TNR), precision, F1-score, false negative rate (FNR), and false positive rate (FPR). An ablation study confirmed the contribution of each module, highlighting the critical role of ensemble CNNs, CAF, and ViT in improving performance. Experimental results demonstrate that the proposed model outperforms conventional transfer learning models and existing state-of-the-art techniques, achieving 97.91% accuracy, along with significant improvements in TPR, TNR, and reduced FNR/FPR. The computational complexity, evaluated in terms of parameters, FLOPs, GPU memory, and inference time, indicates that the proposed model is more demanding than traditional CNNs. Nevertheless, the architecture strikes a practical balance between predictive accuracy and efficiency, making it suitable for real-world clinical applications. These findings underscore the potential of AI-powered hybrid models in expediting prostate cancer diagnosis and enabling timely intervention for improved patient outcomes.
prostate cancer detectionhistopathology image analysishybrid CNN-ViT modelcross-attention fusion
Drug Development Research · مجلد 84 (6) · 1247-1265
Abstract Following the pharmacophoric features of vascular endothelial growth factor receptor 2 (VEGFR‐2) inhibitors, a novel thieno[2,3‐d]pyrimidine derivative has been designed and its activity against VEGFR‐2 has been demonstrated by molecular docking studies that showed an accurate binding mode and an excellent binding energy. Furthermore, the recorded binding was confirmed by a series of molecular dynamics simulation studies, which also revealed precise energetic, conformational, and dynamic changes. Additionally, molecular mechanics with generalized Born and surface area solvation and polymer‐induced liquid precursors studies were conducted and verified the results of the MD simulations. Next, in silico absorption, distribution, metabolism, excretion, and toxicity studies have also been conducted to examine the general drug‐like nature of the designed candidate. According to the previous results, the thieno[2,3‐d]pyrimidine derivative was synthesized. Fascinatingly, it inhibited VEGFR‐2 (IC50 = 68.13 nM) and demonstrated strong inhibitory activity toward human liver (HepG2), and prostate (PC3) cell lines with IC50 values of 6.60 and 11.25 µM, respectively. As well, it was safe and showed a high selectivity index against normal cell lines (WI‐38). Finally, the thieno[2,3‐d]pyrimidine derivative arrested the growth of the HepG2 cells at the G2/M phase inducing both early and late apoptosis. These results were further confirmed through the ability of the thieno[2,3‐d]pyrimidine derivative to induce significant changes in the apoptotic genes levels of caspase‐3, caspase‐9, Bcl‐2 associated X‐protein, and B‐cell lymphoma 2.
thieno[2,3-d]pyrimidine derivativesVEGFR-2 inhibitorsvascular endothelial growth factor receptor 2anticancer drug design
BACKGROUND: The studies on the potential usage of benzene sulfonamide derivatives as anticancer agents are limited. benzene sulfonamide derivatives are currently used as anticancer agents against different breast cancer cell lines, such as MCF-7, lung cancer cells (A549), prostate cancer cells (Du-145), and cervical cells (HeLa). OBJECTIVE: A series of new sulfonamide drugs are synthesized by reacting aldehydes thio-semi-carbazones derivatives with benzene sulphonyl chloride to form benzylidene-N-(phenylsulfonyl) hydrazine-1-carbothioamide derivatives. Studying the anticancer effects against MCF-7 breast carcinoma cell lines and the antioxidant activities of these newly synthesized compounds. METHODS: Studying the anticancer effects against MCF-7 breast carcinoma cell lines and the antioxidant activities of these newly synthesized compounds. To study the anti-breast cancer activity of the newly synthesized compounds, a molecular docking study is used to analyze the binding energy for the nonbonding interactions between the ligands (studied compounds) and receptor (4PYP (pdb code: 4FA2)) against human breast cancer (MCF-7) cells. The bioavailability of all studied compounds is confirmed by pharmacological investigations using Mol inspiration and absorption, distribution, metabolism, excretion, and toxicity online servers. RESULTS: The two derivatives, 2-(4- methoxy benzylidene)-N-(phenylsulfonyl) hydrazine-1-carbothioamide (4c) and 2-(4-dimethylamino) benzylidene)-N-(phenylsulfonyl) hydrazine-1-carbothioamide (4e) show the most potent anticancer effects against MCF-7 breast carcinoma cell lines. Meanwhile, these two derivatives show the lowest antioxidant activities. CONCLUSION: The different spectral techniques were used to confirm the structure of the novel synthesized compounds. Further, 2-(4-(dimethyl amino) benzylidene)-N- (phenylsulfonyl)hydrazine-1-carbothioamide (4e) and 2-(4- methoxy benzylidene)-N-(phenylsulfonyl) hydrazine-1 carbothioamide (4c) were the most potent anticancer derivatives against MCF-7 breast carcinoma cell lines. Furthermore, they exhibited the most potent antioxidant activities. Meanwhile, the 2-benzylidene-N-(phenylsulfonyl) hydrazine-1-carbothioamide (4a) and 2-(4-chloro benzylidene)-N-(phenylsulfonyl) hydrazine-1-carbothioamide (4d) had the lowest antioxidant potentials. The estimated binding energies, inhibition constant, intermolecular energies, and reference RMSD produced from docking for all studied compounds were reported. These values showed that all studied compounds formed stable complexes with the receptor with high binding affinity. It was further noted from the ADMET analysis that compounds 4c, 4d, and 4e have good absorption, low toxicity in the human liver, and medium BBB penetration. Hence, these studied compounds (4c-4e) may be suggested as potential compounds against human breast cancer MCF-7 cells.
Egyptian Journal of Pathology · مجلد 39 (2) · 452-452
Introduction Alpha-methylacyl-CoA (AMACR) is an enzyme of the mitochondria and perixosomes. It was found that it showed great overexpression in prostatic adenocarcinoma, even with minimal foci. TMPRSS2/ERG fusion is one of the common genetic anomalies affecting PCa. A great correlation between positive immunohistochemical (IHC) expression for ERG and the state of fusion has been found, but the diagnostic and prognostic importance of ERG IHC remains undetected. This study aimed to evaluate the differential diagnostic and prognostic significance of both AMACR and ERG in PCa with correlation to the clinicopathological variables.Materials and methods TThe authors reviewed 70 prostatic lesions. Prostatic adenocarcinoma (50 cases), prostatic intraepithelial neoplasia (PIN) (15 with high-grade PIN, five with low-grade PIN), and benign prostatic hyperplasia (10 cases) that were used as a control. Immunohistochemical staining for AMACR and ERG was done. Follow-up of the cases for 18 months was also done.Results A statistically significant difference in the expression of ERG among the examined cases was found. It was negative in control benign prostatic hyperplasia and low-grade PIN cases), positive in 20% of high-grade PIN, and 74% of prostatic adenocarcinoma cases (P<0.01). No statistically significant correlation was found between ERG expression and tumor volume, Gleason sum score, stage, surgical margin, presence of lymphovascular invasion, perinural invasion, distant metastasis, and survival (P>0.05). Regarding AMACR expression, a statistically significant difference in the expression of AMACR among the examined cases was found (negative in benign prostatic hyperplasia, and low PIN cases) to be positive in 33.3% of high-grade PIN and in 62% of prostatic adenocarcinoma cases (P<0.01). A statistically significant correlation was found between AMACR expression and tumor volume, Gleason sum score, surgical margin, presence of lymphovascular invasion, and survival (P<0.05).Conclusion The study provides an additional evidence that IHC expression of AMACR has a role in prostatic carcinoma development. IHC expression of AMACR was absent in benign prostatic lesions. AMACR is an essential tumor marker for the diagnosis and prognosis of prostatic lesions. IHC expression of ERG may have a role in the diagnosis and biological stratification of prostate cancer.
Novel, cyclic peptidomimetics were synthesized by facile acylation reactions using benzotriazole chemistry. Microbiological testing of the synthesized compounds revealed an exceptionally high activity against Candida albicans with a minimum inhibitory concentration (MIC) two orders of magnitude lower than the MIC of the antifungal reference drug amphotericin B. A strikingly high activity was also observed against three Gram-negative bacterial strains (Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus vulgaris), two of which are known human pathogens. Thus the discovered chemotype is a potential polypharmacological agent. The toxicity against mammalian tumor cells was found to be low, as demonstrated in five different human cell lines (HeLa, cervical; PC-3, prostate; MCF-7, breast; HepG2, liver; and HCT-116, colon). The internal consistency of the experimental data was studied using 3D-pharmacophore and 2D-QSAR.